Stryker Corporation (NYSE: SYK) and Trivascular Technologies (NASDAQ:TRIV) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, dividends, valuation, earnings, profitabiliy and analyst recommendations.

Analyst Ratings

This is a breakdown of current ratings for Stryker Corporation and Trivascular Technologies, as provided by MarketBeat.

Stryker Corporation presently has a consensus price target of $139.21, suggesting a potential downside of 4.69%. Given Stryker Corporations higher probable upside, equities research analysts plainly believe Stryker Corporation is more favorable than Trivascular Technologies.

Dividends

Stryker Corporation pays an annual dividend of $1.70 per share and has a dividend yield of 1.2%. Trivascular Technologies does not pay a dividend. Stryker Corporation pays out 38.2% of its earnings in the form of a dividend. Trivascular Technologies has raised its dividend for 6 consecutive years.

Insider and Institutional Ownership

74.3% of Stryker Corporation shares are owned by institutional investors. 7.4% of Stryker Corporation shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Stryker Corporation and Trivascular Technologies net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Stryker Corporation and Trivascular Technologies gross revenue, earnings per share and valuation.

Stryker Corporation has higher revenue and earnings than Trivascular Technologies.

Summary

Stryker Corporation beats Trivascular Technologies on 9 of the 11 factors compared between the two stocks.

About Stryker Corporation

Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Companys segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products. The MedSurg segment includes surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling, emergency medical equipment, intensive care disposable products; reprocessed and remanufactured medical devices, and other related products. The Neurotechnology and Spine segment includes neurovascular products, spinal implant systems and other related products. The Companys products include implants, which are used in joint replacement and trauma surgeries, and other products that are used in a range of medical specialties.

About Trivascular Technologies

Trivascular Technologies, Inc. is a medical device company developing and commercializing technologies to advance minimally invasive treatment of abdominal aortic aneurysms (AAA). The Ovation System, the Companys solution for the treatment of AAA through minimally invasive endovascular aortic repair, or EVAR, is a stent graft platform, providing an alternative to conventional devices. It is designed to specifically address many of the limitations associated with conventional EVAR devices and expand the pool of patients eligible for EVAR. The Company is developing Ovation iX iliac limbs for use with both its Ovation Prime and its Ovation iX and Alto aortic bodies, which are in development. Trivascular is developing Ovation iX aortic bodies for use with both its Ovation Prime and its Ovation iX iliac limbs. The Company is developing an aortic body that together with the iliac limbs makes up the Ovation Alto stent graft.

Receive News & Ratings for Stryker Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Read the rest here:

Trivascular Technologies (TRIV) & Stryker Corporation (SYK) Critical Review - Stock Observer